Literature DB >> 24080464

Elevated serum ubiquitin C-terminal hydrolase-L1 levels in patients with carbon monoxide poisoning.

Li Pang1, Yang Wu1, Ning Dong1, Da-hai Xu1, Da-wei Wang1, Zhi-hao Wang1, Xing-liang Li1, Miao Bian2, Hui-jie Zhao2, Xiao-liang Liu1, Nan Zhang3.   

Abstract

OBJECTIVE: Ubiquitin C-terminal hydrolase-L1 (UCH-L1) has been established as a reliable and potential biomarker of neuronal damage after acute neurologic insults, such as ischemic stroke, subarachnoid hemorrhage, and traumatic brain injury. However, the effect of serum UCH-L1 levels has not been investigated in carbon monoxide (CO)-poisoned patients. The aim of the present study was to evaluate whether serum UCH-L1 levels are a reliable marker of brain damage and the association of UCH-L1 with outcome. DESIGN AND METHODS: This case-control study enrolled 46 CO-poisoned subjects and 30 controls. Using an enzyme-linked immunosorbent assay (ELISA) kit, we studied the temporal profile of serum UCH-L1 levels at 6, 12, 24 and 48 h after acute CO poisoning. Poisoning severity was assessed using the Glasgow Coma Scale (GCS) score. Long-term outcome was assessed using the Glasgow Outcome Scale (GOS) at 6 months after poisoning.
RESULTS: Compared with controls, CO-poisoned patients had significantly elevated serum levels of UCH-L1 at each time point after poisoning. There were significantly higher levels of UCH-L1 in CO-poisoned patients with a lower GCS score as well as in those with a poor 6-month outcome dichotomized GOS.
CONCLUSIONS: Serum levels of UCH-L1 appear to have potential clinical utility in providing valuable information about poisoning severity and outcome after CO poisoning.
© 2013.

Entities:  

Keywords:  Biomarkers; Brain damage; CO; CO poisoning; COHb; ED; ELISA; GCS; GOS; Glasgow Coma Scale; Glasgow Outcome Scale; HBO; HBO therapy; HBOT; NBO; SEM; TBI; UCH-L1; Ubiquitin C-terminal hydrolase L1; carbon monoxide; carboxyhemoglobin; emergency department; enzyme-linked immunosorbent assay; hyperbaric oxygen; normobaric oxygen; standard error of the mean; traumatic brain injury; ubiquitin C-terminal hydrolase-L1

Mesh:

Substances:

Year:  2013        PMID: 24080464     DOI: 10.1016/j.clinbiochem.2013.09.015

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Addressing the needs of traumatic brain injury with clinical proteomics.

Authors:  Sean Shen; Rachel R Ogorzalek Loo; Ina-Beate Wanner; Joseph A Loo
Journal:  Clin Proteomics       Date:  2014-03-28       Impact factor: 3.988

2.  Effects of inhalation of low-dose nitrite or carbon monoxide on post-reperfusion mitochondrial function and tissue injury in hemorrhagic shock swine.

Authors:  Håkon Haugaa; Hernando Gómez; Donald R Maberry; Andre Holder; Olufunmilayo Ogundele; Ana Maria B Quintero; Daniel Escobar; Tor Inge Tønnessen; Hannah Airgood; Cameron Dezfulian; Elizabeth Kenny; Sruti Shiva; Brian Zuckerbraun; Michael R Pinsky
Journal:  Crit Care       Date:  2015-04-22       Impact factor: 9.097

3.  Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study.

Authors:  Ömer Faruk Demirel; İhsan Cetin; Şenol Turan; Tarık Sağlam; Nazım Yıldız; Alaattin Duran
Journal:  Psychiatry Investig       Date:  2017-05-16       Impact factor: 2.505

4.  Serum ubiquitin C-terminal hydrolase L1 predicts cognitive impairment in patients with acute organophosphorus pesticide poisoning.

Authors:  Li Pang; Junlan Liu; Wei Li; Yan Xia; Jihong Xing
Journal:  J Clin Lab Anal       Date:  2019-06-14       Impact factor: 2.352

5.  Analysis of Clinical Related Factors of Neonatal Hand-Foot-Mouth Disease Complicated With Encephalitis.

Authors:  Yanling Fang; Chaowei Lian; Dali Huang; Liping Xu
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.086

Review 6.  Neurocognitive sequelae after carbon monoxide poisoning and hyperbaric oxygen therapy.

Authors:  Ke Ning; Yan-Yan Zhou; Ning Zhang; Xue-Jun Sun; Wen-Wu Liu; Cui-Hong Han
Journal:  Med Gas Res       Date:  2020 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.